Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Harmanjit Singh, Jatin Sharma, Pallavi Sikarwar & Ashish Kumar Kakkar. (2023) Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer: current evidence and future directions. Expert Review of Clinical Pharmacology 16:1, pages 39-47.
Read now
Read now
Ofri Mosenzon, Eden M. Miller & Mark L. Warren. (2020) Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients. Postgraduate Medicine 132:sup2, pages 37-47.
Read now
Read now
André Jacques Scheen. (2018) The safety of gliptins : updated data in 2018. Expert Opinion on Drug Safety 17:4, pages 387-405.
Read now
Read now
Tomas Lafarga & Maria Hayes. (2017) Bioactive protein hydrolysates in the functional food ingredient industry: Overcoming current challenges. Food Reviews International 33:3, pages 217-246.
Read now
Read now
Articles from other publishers (37)
Hitoshi Ishii, Nozomu Kamei, Dai Shimono, Tetsuji Niiya, Takahiro Tosaki, Toru Kitazawa, Daisuke Suzuki, Yutaka Wakasa, Hiroaki Seino, Mariko Oishi, Hiroshi Ohashi, Kenshi Higami & Hiroaki Akai. (2023) Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study). Diabetes Therapy.
Crossref
Crossref
Kunika Saini, Smriti Sharma & Yousuf Khan. (2023) DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Sunayana Vikhe, Rahul Kunkulol & Dipak Raut. (2023) In Silico and In Vivo Studies of Decursin Isolated From the Ethanolic
Extract of Feronia elephantum Correa (Rutaceae) Bark as a Potential Antidiabetic
and Antihyperlipidemic Agents in STZ-induced Diabetic Rats. Letters in Drug Design & Discovery 20:5, pages 517-535.
Crossref
Crossref
Alexandra Chirila, Mary E Nguyen, Jill Tinmouth & Ilana J Halperin. (2023) Preparing for Colonoscopy in People with Diabetes: A Review with Suggestions for Clinical Practice. Journal of the Canadian Association of Gastroenterology 6:1, pages 26-36.
Crossref
Crossref
Pallavi Kishor Vawhal, Shailaja B. Jadhav, Sumit Kaushik, Kahnu Charan Panigrahi, Chandan Nayak, Humaira Urmee, Sharuk L. Khan, Falak A. Siddiqui, Fahadul Islam, Aziz Eftekhari, Abdullah R. Alzahrani, Mohd Fahami Nur Azlina, Md. Moklesur Rahman Sarker & Ibrahim Abdel Aziz Ibrahim. (2023) Coumarin-Based Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Pre-ADME Analysis, Toxicity Profile, Computational Analysis, and In Vitro Enzyme Assay. Molecules 28:3, pages 1004.
Crossref
Crossref
Joanna Wojciechowska, Wojciech Krajewski, Tomasz Zatoński & Joel Rodriguez-Saldana. 2023. The Diabetes Textbook. The Diabetes Textbook
1041
1060
.
Federica Ferrari, Antonio Moretti & Roberto Federico Villa. (2022) Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacology & Therapeutics 239, pages 108277.
Crossref
Crossref
Anuradha K. Gajjar & Chirag D. Pathak. (2022) Synthesis of 5(S)-Methyl-L-Proline Containing Peptidomimetic Compounds
and their In Vitro Evaluation for Dipeptidyl Peptidase-4 Inhibition. Letters in Drug Design & Discovery 19:4, pages 350-365.
Crossref
Crossref
Ajinkya Chavan, Kratika Daniel & Ansar M. Patel. (2022) In-silico Exploration of Phytoconstituents of Gymnema sylvestre as Potential
Glucokinase Activators and DPP-IV Inhibitors for the Future Synthesis
of Silver Nanoparticles for the Treatment of Type 2 Diabetes Mellitus. Current Enzyme Inhibition 18:1, pages 47-60.
Crossref
Crossref
Prerana A. Chavan & Shailaja B. Jadhav. (2022) Synthesis, Characterization and Screening of Some Novel 2-Methyl-N'-
[(Z)-Substituted-Phenyl ethylidene] Imidazo [1, 2-a] Pyridine-3-Carbohy
drazide Derivatives as DPP-IV Inhibitors for the Treatment of Type 2 Diabetes
Mellitus. Letters in Drug Design & Discovery 19:2, pages 160-174.
Crossref
Crossref
Chin-Ying Ray, Victor Chien-Chia Wu, Chun-Li Wang, Hui-Tzu Tu, Yu-Tung Huang, Chang-Fu Kuo & Shang-Hung Chang. (2021) Hypoglycemia Associated With Drug–Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors. Frontiers in Pharmacology 12.
Crossref
Crossref
Jing Huang, Yuntao Jia, Shusen Sun & Long Meng. (2020) Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. BMC Pharmacology and Toxicology 21:1.
Crossref
Crossref
Yayoi Nishida, Yasuo Takahashi, Kotoe Tezuka, Hayato Akimoto, Tomohiro Nakayama & Satoshi Asai. (2020) Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus. BMC Pharmacology and Toxicology 21:1.
Crossref
Crossref
Islamudin Ahmad, Ayun Erwina Arifianti, Aditya Sindu Sakti, Fadlina Chany Saputri & Abdul Mun’im. (2020) Simultaneous Natural Deep Eutectic Solvent-Based Ultrasonic-Assisted Extraction of Bioactive Compounds of Cinnamon Bark and Sappan Wood as a Dipeptidyl Peptidase IV Inhibitor. Molecules 25:17, pages 3832.
Crossref
Crossref
Wen Han, Yao Li, Jiangting Cheng, Jing Zhang, Dingwen Chen, Mingqiao Fang, Guangheng Xiang, Yanqing Wu, Hongyu Zhang, Ke Xu, Hangxiang Wang, Ling Xie & Jian Xiao. (2020) Sitagliptin improves functional recovery via GLP‐1R‐induced anti‐apoptosis and facilitation of axonal regeneration after spinal cord injury. Journal of Cellular and Molecular Medicine 24:15, pages 8687-8702.
Crossref
Crossref
Fang Zhang, Shishi Xu, Lizhi Tang, Xiaohui Pan & Nanwei Tong. (2020) Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology 11.
Crossref
Crossref
Morten Hasselstrøm Jensen, Claus Dethlefsen, Ole Hejlesen & Peter Vestergaard. (2019) Association of severe hypoglycemia with mortality for people with diabetes mellitus during a 20-year follow-up in Denmark: a cohort study. Acta Diabetologica 57:5, pages 549-558.
Crossref
Crossref
Martin Haluzík. (2020) Incretin-based treatment of diabetes and cardiovascular complications. Vnitřní lékařství 66:2, pages 74-80.
Crossref
Crossref
Rhiannon N. Hardwick, Catherine J. Betts, Jessica Whritenour, Radhakrishna Sura, Maike Thamsen, Elad H. Kaufman & Kristin Fabre. (2020)
Drug-induced skin toxicity: gaps in preclinical testing cascade as opportunities for complex
in vitro
models and assays
. Lab on a Chip 20:2, pages 199-214.
Crossref
Crossref
Rachael Williams, Wolfgang Kothny, Carmen Serban, Sandra Lopez‐Leon, Frank de Vries & Raymond Schlienger. (2019) Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: A European multidatabase, noninterventional, postauthorization safety study. Endocrinology, Diabetes & Metabolism 2:3.
Crossref
Crossref
Rachael Williams, Wolfgang Kothny, Carmen Serban, Sandra Lopez‐Leon & Raymond Schlienger. (2019) Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study. Endocrinology, Diabetes & Metabolism 2:2, pages e00052.
Crossref
Crossref
Patrick M. Jedlowski, Charisse H. Te, Robert J. Segal & Maryam T. Fazel. (2018) Cutaneous Adverse Effects of Diabetes Mellitus Medications and Medical Devices: A Review. American Journal of Clinical Dermatology 20:1, pages 97-114.
Crossref
Crossref
Su Jin Lee, Kyoung Hwa Ha, Jung Hyun Lee, Hokyou Lee, Dae Jung Kim & Hyeon Chang Kim. (2019) Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study. PLOS ONE 14:2, pages e0211959.
Crossref
Crossref
Jiyuan Si, Ranran Meng, Peng Gao, Feifei Hui, Yu Li, Xianhu Liu & Bin Yang. (2019) Linagliptin protects rat carotid artery from balloon injury and activates the NRF2 antioxidant pathway. Experimental Animals 68:1, pages 81-90.
Crossref
Crossref
Joanna Krajewska, Wojciech Krajewski & Tomasz Zatoński. 2019. The Diabetes Textbook. The Diabetes Textbook
919
937
.
G P Fadini, A Solini, M L Manca, G Zatti, I Karamouzis, A Di Benedetto, L Frittitta & A Avogaro. (2018) Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study. Acta Diabetologica 55:11, pages 1121-1129.
Crossref
Crossref
Yousuf M. Al Suleimani, Aly M. Abdelrahman, Turan Karaca, Priyadarsini Manoj, Mohammed Ashique, Abderrahim Nemmar & Badreldin H. Ali. (2018) The effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on gentamicin nephrotoxicity in mice. Biomedicine & Pharmacotherapy 97, pages 1102-1108.
Crossref
Crossref
Bhumika D. Patel, Shraddha V. Bhadada & Manjunath D. Ghate. (2017) Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors. Bioorganic Chemistry 72, pages 345-358.
Crossref
Crossref
Cristina Bianchi, Giuseppe Daniele, Angela Dardano, Roberto Miccoli & Stefano Del Prato. (2017) Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs 77:3, pages 247-264.
Crossref
Crossref
Chalermrat Bunchorntavakul & K. Rajender Reddy. (2017) Drug Hepatotoxicity. Clinics in Liver Disease 21:1, pages 115-134.
Crossref
Crossref
Shan-yao Ma, Meng-meng Ning, Qing-an Zou, Ying Feng, Yang-liang Ye, Jian-hua Shen & Ying Leng. (2016) OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition. Acta Pharmacologica Sinica 37:10, pages 1359-1369.
Crossref
Crossref
Sunil Amin, Paolo Boffetta & Aimee L. Lucas. (2016) The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer. Gut and Liver 10:5, pages 665-671.
Crossref
Crossref
Lucie Sromova, Petr Busek, Helena Posova, Jana Potockova, Pavel Skrha, Michal Andel & Aleksi Sedo. (2016) The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 118, pages 183-192.
Crossref
Crossref
Bo Ahrén & James E. Foley. (2016) Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia 59:5, pages 907-917.
Crossref
Crossref
Adrienn Kazsoki, Ida Fejős, Tamás Sohajda, Wei Zhou, Wenhui Hu, Lajos Szente & Szabolcs Béni. (2016) Development and validation of a cyclodextrin-modified capillary electrophoresis method for the enantiomeric separation of vildagliptin enantiomers. ELECTROPHORESIS 37:10, pages 1318-1325.
Crossref
Crossref
Marcus May & Christoph Schindler. (2016) Clinically and pharmacologically relevant interactions of antidiabetic drugs. Therapeutic Advances in Endocrinology and Metabolism 7:2, pages 69-83.
Crossref
Crossref
Baptist Gallwitz. (2016) Glucagon-like peptide-1 and gastric inhibitory polypeptide. Current Opinion in Endocrinology, Diabetes & Obesity 23:1, pages 23-27.
Crossref
Crossref